MarketCapExport financials
Karuna Therapeutics (KRTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Karuna Therapeutics Balance Sheet 2023-2011 | KRTX
Brief overview of Karuna Therapeutics's financial position
The review uses the five latest available annual reports between 2019 and 2023.
Assets advanced +240% to $1.3 billion from $393 million; annual growth near 35.8% reflects a fast increase in scale.
Asset growth of +240% came with a +2,537.5% rise in liabilities. Financial leverage became more prominent.
The equity-to-assets ratio is 93.9%, compared with 99.2% five periods ago. The balance sheet has a substantial internal cushion.
Negative net debt of -$169.1 million means cash holdings are larger than debt obligations.
Cash accounts for 13.9% of assets versus 53.2% initially. The change indicates the degree of financial flexibility.
The balance sheet carries negative retained earnings of -$997.9 million. The figure may result from accumulated losses or an active capital return policy.
Overall assessment
Karuna Therapeutics's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.
Annual Balance Sheet Karuna Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-169 M | -243 M | -199 M | -50.4 M | -209 M | -85.4 M | 9.72 M | - | - | - | - | - | - |
Long Term Debt |
13.8 M | 3.05 M | 5.33 M | 1.84 M | - | - | 3.98 M | - | - | - | - | - | - |
Long Term Debt Current |
2.84 M | 2.28 M | 2.18 M | 844 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 150 K | 102 K | 3.99 M | - | - | - | - | - | - |
Total Current Liabilities |
68.1 M | 33.9 M | 20.2 M | 6.85 M | 2.96 M | 1.2 M | - | - | - | - | - | - | - |
Total Liabilities |
82 M | 37.1 M | 25.6 M | 8.69 M | 3.11 M | 3.81 M | 15.5 M | - | - | - | - | - | - |
Retained Earnings |
-998 M | -564 M | -288 M | -144 M | -75.5 M | -31.6 M | -14 M | - | - | - | - | - | - |
Total Assets |
1.34 B | 1.16 B | 528 M | 348 M | 393 M | 15.9 M | 2.13 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
186 M | 248 M | 207 M | 53 M | 209 M | 8.9 M | - | - | - | - | - | - | - |
Book Value |
1.25 B | 1.13 B | 502 M | 339 M | 390 M | 12 M | -13.4 M | - | - | - | - | - | - |
Total Shareholders Equity |
1.25 B | 1.13 B | 502 M | 339 M | 390 M | -29.9 M | -13.4 M | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Karuna Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
13.8 M | 13.8 M | 2.69 M | 3.05 M | 3.61 M | 4.18 M | 4.76 M | 5.33 M | 5.89 M | 6.44 M | 1.62 M | 1.84 M | 2.06 M | 1.94 M | 2.12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
62.8 M | 52.5 M | 28 M | 37.1 M | 44.5 M | 28.1 M | 20.8 M | 25.6 M | 21.8 M | 16.8 M | 8.35 M | 8.69 M | 7.18 M | 6.01 M | 4.78 M | 3.11 M | 1.7 M | 2.45 M | 3.11 M | 3.81 M | 3.81 M | 3.81 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-884 M | -765 M | -662 M | -564 M | -488 M | -411 M | -346 M | -288 M | -260 M | -209 M | -175 M | -144 M | -120 M | -101 M | -84.2 M | -75.5 M | -67.7 M | -58.7 M | -75.5 M | -31.6 M | -31.6 M | -31.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.39 B | 1.47 B | 1.52 B | 1.16 B | 1.23 B | 434 M | 474 M | 528 M | 540 M | 577 M | 593 M | 348 M | 364 M | 378 M | 390 M | 393 M | 164 M | 79.4 M | 393 M | 15.9 M | 15.9 M | 15.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
184 M | 264 M | 563 M | 248 M | 628 M | 136 M | 176 M | 207 M | 252 M | 346 M | 354 M | 53 M | 44.8 M | 134 M | 191 M | 209 M | 54.1 M | 10.5 M | 209 M | 8.9 M | 8.9 M | 8.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.32 B | 1.42 B | 1.49 B | 1.13 B | 1.18 B | 405 M | 454 M | 502 M | 518 M | 560 M | 585 M | 339 M | 357 M | 372 M | 385 M | 390 M | 163 M | 76.9 M | 390 M | 12 M | 12 M | 12 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.32 B | 1.42 B | 1.49 B | 1.13 B | 1.18 B | 405 M | 454 M | 502 M | 518 M | 560 M | 585 M | 339 M | 357 M | 372 M | 385 M | 390 M | 163 M | -47 M | 390 M | -29.9 M | -29.9 M | -29.9 M | -15.7 M | -13.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Karuna Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Britain
Israel
Germany
Canada
Russia
Schweiz
